Overview

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

Phase:

Phase 2

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.